secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001628280-24-021381
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience Q1 FYARRO sales $5.4M; PRECISION1 fully enrolled; net loss $18.3M
--------------------------------------------------------------------------------

- FYARRO net sales $5.4M, down 8.8% YoY due to distributor ordering and fewer patient initiations.
- Net loss $18.3M vs $15.2M in Q1 2023; cash $88.3M expected to fund operations into Q4 2025.
- PRECISION1 trial fully enrolled; two-thirds interim analysis expected Q3 2024, full data early 2025.
- Terminated Mirati/BMS collaboration for adagrasib combo; prioritizing Phase 2 trials in EEC and NETs.
- Management expects return to sales growth in Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828024021381/0001628280-24-021381-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828024021381/aadi-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-021381

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer